Gene modified cell therapy such as CAR-T cells is one of the most promising advanced therapy medicinal products (ATMP) to fight against cancer. These therapies typically use lentiviral vectors to transfer a gene of interest and modify patient’s cells. All the raw material used during the lentiviral vector manufacturing must be carefully selected based on different parameters such as quality, performance, supplier, etc. In this project, we generated CAR-T cells based on different plasmid constructs expressing a fusion protein CAR to track transduction efficiency. We first built different plasmid constructs using the plasmid engineering service from Polyplus, then encapsulate this gene of interest using a lentiviral vector produced with FectoVIR®-LV, transduce CD4+ CD8+ T cells from peripheral blood with this lentiviral vector, expand them for 12 days and finally test the efficiency of the transduced CAR-T cells using a killing assay.

Overview of CAR-T Cell Generation Using Optimized Plasmid Design and Lentiviral Vector Production

Download Poster

Need certificate of analysis ?

In order to download a product protocol or a certificate of analysis, please create an account on Polyplus®Portal .

Create an account to discover our

  • Certificate of Analysis
  • Plasmid Design Platform
  • Product Protocols
  • All exclusive gated content
  • e-Newsletter

Create Account Now

Other sources

Check our FAQs

These FAQs are organized by application to guide you to find the best answer possible.

Product Documents

You have access to all the documents related to the Polyplus Products such as MSDS, NHPS and Posters.

Polyplus-transfection Database

Search for publications in the Transfection Database with Polyplus transfection reagents or for transfection conditions. Over 6000 publications, 1000 cell lines and primary cells available.


This lexicon will help you to understand the different terms related to Polyplus products and services.